COMMUNIQUÉS West-GlobeNewswire

Shire plc : New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism

20/03/2018 - 08:00

New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism - Clinical and real-world data on chronic hypoparathyroidism provides new insights [...]

Motif Bio Update on NDA Submission for Iclaprim

20/03/2018 - 08:00

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and [...]

PCI Biotech: Full year 2017 report - a transformative year

20/03/2018 - 07:31

Oslo (Norway), 20 March 2018 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its full year result. Please find enclosed the full year 2017 presentation. 2017 was a year of [...]

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

20/03/2018 - 07:15

Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development of novel implantable and [...]

Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy

20/03/2018 - 07:01

Pratteln, Switzerland, March 20, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports the Group's audited financial results for 2017. Net revenues from sales of lead product Raxone® (idebenone) increased by 21% compared [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

20/03/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 20 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Helix BioPharma Corp. Announces Fiscal Second Quarter 2018 Results

20/03/2018 - 01:19

RICHMOND HILL, Ontario, March 19, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP ) (FRANKFURT: HBP ) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates [...]

PCI Biotech: Annual Report 2017

19/03/2018 - 23:01

Oslo (Norway), March 19, 2018 The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2017 and the report is attached. The Annual Report 2017 is also available on the company's website www. [...]

Immunovaccine Researchers to Present New Preclinical Data at AACR Annual Meeting 2018

19/03/2018 - 22:05

HALIFAX, Nova Scotia, March 19, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Company will present research on the anti-cancer [...]

CohBar, Inc. to Announce 2017 Fourth Quarter Financial Results and Host Conference Call for Shareholders on April 2, 2018

19/03/2018 - 21:35

MENLO PARK, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR ) (TSXV:COB.U), an innovative biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, [...]

Brainsway Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

19/03/2018 - 21:30

Increased market demand and new leasing model continue to generate significant sales growth Total minimum committed revenue projection is record $27 million for year-end 2017, up 142% versus year-end 2016 Strong balance [...]

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

19/03/2018 - 21:30

- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic Anemia (AIHA) and [...]

AXIM Biotechnologies Reports Year End 2017 Results

19/03/2018 - 21:15

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced financial results for the quarter and year [...]

T2 Biosystems to Present at the 17th Annual Needham Healthcare Conference

19/03/2018 - 21:05

LEXINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in [...]

aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update

19/03/2018 - 21:05

SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]

Delcath to Present at Oppenheimer 28th Annual Healthcare Conference

19/03/2018 - 21:05

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, [...]

Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference

19/03/2018 - 21:05

SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT ), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today [...]

HealthEquity Reports Fourth Quarter and Fiscal Year Ended January 31, 2018 Financial Results

19/03/2018 - 21:04

Highlights of the fiscal year include: Revenue of $229.5 million, an increase of 29% compared to FY17. Net income of $47.4 million, an increase of 80% compared to FY17. Net income per diluted share of $0.77, compared to [...]

AIT Therapeutics Reports Year End 2017 Financial Results

19/03/2018 - 21:01

Expects first regulatory filing for the NO Generator and Delivery System in persistent pulmonary hypertension of the newborn (PPHN) by end of 2018 Closed global, exclusive license for revolutionary NO Generator and [...]